emicizumab: Clinical Trials

38 trials of emicizumab, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

11 completed, 8 recruiting, 4 active not recruiting, 4 terminated. 18 Phase 3, 9 Phase 4, 5 Phase 2, 2 Phase 1, 1 Not applicable.

By phase and status

PhaseTrialsStatus
Phase 318Completed 7, Withdrawn 3, Active not recruiting 2, Recruiting 2, Terminated 2, Not yet recruiting 1, Unknown 1
Phase 49Recruiting 2, Terminated 2, Unknown 2, Active not recruiting 1, Not yet recruiting 1, Withdrawn 1
Phase 25Active not recruiting 2, Completed 1, Not yet recruiting 1, Unknown 1
Phase 12Completed 1, Recruiting 1
Not applicable1Completed 1

Follow emicizumab: new trials by email Literature Review of emicizumab trials Research Report on emicizumab

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Understanding Treatment Outcomes and Immunologic Mechanisms in Altuviiio Immune Tolerance Induction
efanesoctacog alpha, Emicizumab - Hemophilia A With Inhibitor
Phase 4Not yet recruitingVersiti Blood Health152026-12-012026-07-27
SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis
Emicizumab, FEIBA, rFVIIa - Hemophilia A
Phase 3WithdrawnEmory University2026-09-012026-11-06
TG-INSIGHT With Joint POCUS, Hemostatic Potential in Patients With Severe Hemophilia A on Novel Replacement and Substitution FVIII Therapies
Half-life factor VIII based replacement therapy, Non-FVIII based replacement therapy - Hemophilia A, Factor VIII (FVIII)
RecruitingUniversity of Texas Southwestern Medical Center602026-07-222026-09-29
A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A
NXT007, Emicizumab - Hemophilia A
Phase 3RecruitingHoffmann-La Roche3602026-04-272026-11-03
A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand Disease
Emicizumab, von Willebrand Factor (VWF) Concentrates, Factor VIII (FVIII) Concentrates - Von Willebrand Disease, Type 3
Phase 3RecruitingHoffmann-La Roche752025-06-272026-11-16
Low Dose Emicizumab vs Low Dose Factor VIII in Prophylaxis in Hemophilia A Patients
Emicizumab Injection, Factor VIII (FVIII) - Hemophilia A
Phase 2 / Phase 3Not yet recruitingDhaka Medical College202025-06-012025-04-22
Real-World Joint Outcomes After Selective Transition to Low-Dose Emicizumab in Pediatric Hemophilia A
Switching to low dose emicizumab - Hemophilia A Patient
Phase 2 / Phase 3Active not recruitingChulalongkorn University182025-06-012026-02-27
Real World Use of Emicizumab in Infants and Children Ages 0-3 Years With Hemophilia A
HEMLIBRA - Hemophilia A
CompletedMontefiore Medical Center712024-08-012025-09-08
A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Preventive Treatment With Emicizumab
Fitusiran (SAR439774), Clotting factor concentrates (CFC) or bypassing agents (BPA), Antithrombin concentrate (ATIIIC) - Hemophilia A
Phase 4RecruitingSanofi202024-03-012026-09-23
Health-Related Quality of Life Outcomes and Bleeding Rates Among Patients With Severe Hemophilia A on Emicizumab
Emicizumab - Hemophilia A
UnknownNewark Beth Israel Medical Center502023-12-012023-10-30
Prevention of Bleeding in Patients With Moderate and Severe Hemophilia A Playing Sports: A Comparison Between Factor VIII and Emicizumab Prophylaxis
Emicizumab, FVIII - Hemophilia A
RecruitingWayne State University722023-08-162026-07-02
Comparison of Outcomes Between Low Dose Emicizumab and Factor VIII in Clinically Severe Hemophilia A
"Emicizumab", "HEMLIBRA®" - Severe Hemophilia A Without Inhibitor, Joint Bleed
Phase 2 / Phase 3UnknownChulalongkorn University152023-06-222024-03-05
Emicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia A
Emicizumab - Von Willebrand Disease, Type 3, Concomitant VWD and Hemophilia
Phase 1RecruitingBleeding and Clotting Disorders Institute Peoria, Illinois402022-11-012026-04-03
Pharmacokinetic-guided Dosing of Emicizumab
Emicizumab - PK-guided dose reduction, Emicizumab - Dosis continuation group, Emicizumab - Dose adjustment group - Hemophilia A With Inhibitor, Hemophilia A Without Inhibitor
Phase 4UnknownKathelijn Fischer952022-09-082024-03-20
Emicizumab in Patients With Acquired Hemophilia A
emicizumab - Acquired Hemophilia A
Phase 2Active not recruitingUniversity of Washington512022-08-312025-11-05
Hemlibra in Mild Hemophilia A
Emicizumab - Factor VIII Deficiency, Congenital
Phase 4RecruitingIndiana Hemophilia &Thrombosis Center, Inc.202022-07-252024-03-15
A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxis
Emicizumab - Severe Hemophilia A, Moderate Hemophilia A
Phase 4Active not recruitingHoffmann-La Roche1362022-06-202026-10-23
Emicizumab PUPs and Nuwiq ITI Study
Nuwiq (low dose protocol), HEMLIBRA, Nuwiq (Atlanta protocol) - Hemophilia A
Phase 3WithdrawnEmory University2022-02-172024-01-05
The Hemophilia Inhibitor Eradication Trial
Eloctate ITI, Emicizumab - Hemophilia A With Inhibitor
Phase 3TerminatedMargaret Ragni12021-11-012023-02-21
The Hemophilia Inhibitor Prevention Trial
Eloctate Injectable Product, Emicizumab Injection [Hemlibra] - Hemophilia A Without Inhibitor
Phase 3TerminatedMargaret Ragni12021-10-112023-04-11

Showing 20 of 38. Sign in to see all of them.

Conditions studied

Hemophilia A (33)  ·  Factor 8 deficiency, acquired (2)  ·  Hemarthrosis (2)  ·  von Willebrand Disease, Type 3 (2)  ·  Hematologic Diseases (1)  ·  Hemophilia B (1)  ·  Hemorrhage (1)  ·  Hemostatic Disorders (1)

Sponsors

Hoffmann-La Roche (12)  ·  Emory University (3)  ·  Margaret Ragni (3)  ·  Chulalongkorn University (2)  ·  Genentech, Inc. (2)  ·  Indiana Hemophilia &Thrombosis Center, Inc. (2)  ·  University of Texas Southwestern Medical Center (2)  ·  Bleeding and Clotting Disorders Institute Peoria, Illinois (1)  ·  Children's Hospital Los Angeles (1)  ·  Cliniques universitaires Saint-Luc- Université Catholique de Louvain (1)  ·  Dhaka Medical College (1)  ·  GWT-TUD GmbH (1)  ·  Kathelijn Fischer (1)  ·  Montefiore Medical Center (1)  ·  Newark Beth Israel Medical Center (1)

Countries

United States (29)  ·  Germany (11)  ·  Spain (10)  ·  United Kingdom (9)  ·  Italy (8)  ·  France (7)  ·  South Africa (7)  ·  Australia (6)  ·  Belgium (6)  ·  Canada (6)  ·  Japan (6)  ·  Poland (6)  ·  Netherlands (5)  ·  Brazil (4)  ·  Taiwan (4)

Top investigators

Margaret V Ragni, MD, MPH (3)  ·  Amy D Shapiro, MD (2)  ·  Robert Sidonio, MD (2)  ·  Akhil R. Biswas, MBBS, FCPS (1)  ·  Andreas Tiede, Prof. Dr. (1)  ·  Guy Young, MD (1)  ·  Jennifer Davila, MD (1)  ·  Jessica Garcia, MD (1)  ·  Jonathan C Roberts, MD (1)  ·  Meera Chitlur, MD (1)  ·  Rebecca Kruse-Jarres, MD, MPH (1)

Results publications

PMID 35939785, PMID 31697801, PMID 23731246, PMID 23815950, PMID 25059285, PMID 28691557, PMID 30157389, PMID 10968546, PMID 1202003, PMID 19995408, PMID 22530687, PMID 22733686, PMID 22776238, PMID 24628543, PMID 25854144, PMID 26674820, PMID 29296836, PMID 30430726, PMID 30997536, PMID 31003963, PMID 31003964, PMID 3418398, PMID 34435432, PMID 34589194, PMID 35905294, PMID 36636993, PMID 36716761, PMID 37858328, PMID 38127586, PMID 38222041, PMID 38853005, PMID 39737816, PMID 40795229, PMID 42290320, PMID 8141115, PMID 9873794

NIH funding

2016 (4), 2023 (3), 2015 (1), 2019 (1), 2025 (1)